Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System

Journal of Medical Economics

Volumn 12, Issue 4, 2009, Pages 317-324

  Fuller, M ^a   Shermock, K ^b   Russo, P ^c   Secic, M ^d   Dirani, R ^e   Vallow, S ^e   Flanders, S ^e  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c PRC Health Services Research and Management Consulting   (United States)

^d Secic Statistical Consulting Inc   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Hospitalisation; Resource utilisation; Risperidone long acting therapy; Schizophrenia; Veterans affairs

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRAZODONE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DRUG COST; DRUG DOSE INCREASE; DRUG EXPOSURE; FEMALE; GERIATRIC PATIENT; GERONTOPSYCHIATRY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; MENTAL PATIENT; OUTPATIENT CARE; PATIENT COMPLIANCE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT DURATION; UNITED STATES; VETERAN;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; HOSPITALIZATION; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; OHIO; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; VETERANS HEALTH;

EID: 72749111412     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903303902     Document Type: Article

References (25)

1. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006;67(Suppl 5):15-18.
2. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132
3. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month, open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-1257
4. Simpson GM, Mahmoud RA, Lasser RA, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2003;67:1194-1203
5. Locklear J, Lasser R, Zhu Y, et al. Hospitalization during long-term treatment with long acting risperidone. Poster presented at: 2004 Institute on Psychiatric Services' Scientific Program, October 6-10, 2004, Atlanta, GA.
6. Llorca P-M, Devos E, Eerdekens M, et al. Re-hospitalization rates with long-acting risperidone are lower than those reported for other antipsychotics. Poster presented at: the XXII Biennial Meeting of the Collegium Internationale Neuro-Psychopharmacologium, June 23-27, 2002, Montreal, Canada.
7. Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 2005;23(Suppl 1):3-16.
8. Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(Suppl 1):75-89.
9. Chue PS, Heeg B, Buskens E, et al. Modeling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005;23(Suppl 1):62-74.
10. Weiden PJ, Kozma C, Groqq A, et al. Partial compliance and risk rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-891
11. ABILIFY (aripiprazole) [package insert]. Princeton, NJ: Bristol-Myers Squibb, Rockville, MD: Otsuka America Pharmaceutical, Inc., 2007.
12. ZYPREXA (olanzapine) [package insert]. Indianapolis, IN: Eli Lilly and Company, 2007.
13. SEROQUEL (quetiapine) [package insert]. Wilmington, DE: AstraZeneca, 2007.
14. RISPERIDAL (risperidone) [package insert]. Titusville, NJ: Janssen, LP, 2007.
15. GEODON (ziprasidone) [package insert]. New York, NY: Pfizer, Inc., 2007.
16. Hosalli P, Davis JM. Depot risperidone for schizophrenia. Cochrane Database Syst Rev 2003;4:CD004161.
17. Taylor DM, Young CL, Mace S, et al. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004;65:1076-1083
18. Muirhead D, Harvey C, Ingram G. Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes. Aust N Z J Psychiatry 2006;40:595-605.
19. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30:437-452
20. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003;64(Suppl 16):34-40.
21. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308-1315
22. Olivares JM, Rodriguez-Martinez A, et al; e-STAR Study Group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53.
23. Olivares JM, Peuskens J, Pecenak J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009; Jul 15 [Epub ahead of print].
24. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-296
25. Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 2005;8:27-36.